Market Study on Expected Growth for Rare Disease Treatment Market

It is estimated that, approximately 5% of the global population suffer from a rare disease and half of the global population affected by rare diseases are children, which makes rare disease treatment a deliberating concern for children across the globe. There are around 7000 known rare diseases which are one of the most complex healthcare challenge for researchers and health professionals as most of them are difficult to diagnose due heterogeneity in disease epidemiology. Rare diseases that affect 200,000 people in the U.S. (as per FDA definition) or 1 in 2000 population in Europe, are typically genetic in nature and thus present a huge unmet need of potential treatment regimes in the market. As per World Health Organization, 80% of rare diseases are caused due to genetic abnormality and are inherited for generations. Approximately 5 % of rare diseases have treatment and most of the current therapeutic approaches include gene therapy and cell therapy. A significant gap between demand and supply of rare disease dugs is foreseen to create a massive opportunity for manufacturers and researchers in the area of rare disease treatment.

View Sample Report @ http://www.persistencemarketresearch.com/samples/12862

Rare disease drug development was so far neglected or given less importance due to lower profitability as there are less number of patients deemed eligible for treatment by such drugs. However, incentives offered by Orphan Drug Act (ODA) in the U.S. and EU such as tax reduction and market exclusivity is expected to boost the global market for rare disease treatment. Since, the enactment of ODA, FDA has approved more than 480 orphan drugs and 47% of new drugs approved in 2015 were drugs for rare disease treatment. Moreover, the global market for rare disease treatment is expected to gain traction owing to development of new approaches for rare disease treatment such as regenerative medicine, personalized medicine, drug repurposing and repositioning etc. Unlike other biopharmaceutical drugs low competition in the rare disease treatment market encourages new drug developers to invest in the research and development for rare disease treatment.

High cost of treatment and challenges to reimbursement for rare disease treatment are the factors limiting the growth of global rare disease treatment market. For instance, the average annual cost for treatment with Zavesca – a substrate reduction therapy for treatment of type 1 Gaucher disease is approximately US$ 294,840 per year. Treatment for many rare disease sub-types such as Niemann-Pick Disease, Cystinosis etc. is often very expensive due to lack of coverage for these rare disease treatment by provincial and national health plans.

On the basis of regional presence, global rare disease treatment market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America will continue to dominate the global rare disease treatment market due to favorable reimbursement policies and prominent presence of key players in the region. Asia Pacific is expected to grow at highest CAGR over the forecast period partly due to entry of new players such as JCR Pharmaceuticals Co. Ltd. and increasing awareness towards rare diseases. MEA is expected to hold least share in global rare disease treatment market due to lack of coherent strategies for access to healthcare support for rare diseases.

Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/12862

Some of the players operating in global rare disease treatment market Novartis AG, Shire PLC, Pfizer, Inc., Actelion Ltd., Bristol Myers Squibb, AstraZeneca PLC, Amgen Inc., Biogen Inc., Merck KGaA, Daiichi Sankyo Company, Sanofi, Eli Lilly and Company and others. Research collaborations and partnerships is emerging as a major trend among players in rare disease treatment market as development of rare disease is costly and less profitable. For instance, Protalix Biotherapeutics Inc. and Zacharon Pharmaceuticals collaborated with Pfizer Inc. for development of rare disease treatment. Mergers and acquisitions in rare disease treatment market are preferred by the leading players to gain immediate growth effect. For instance, in January 2015 Shire plc. acquired Dyax Corp. for US$ 5.9 Bn and expanded its hereditary angioedema (HAE) portfolio – a rare disease of blood. Subsequently in 2016, Shire plc. acquired Baxalta Incorporated for US$ 32 Bn and became a leader in global rare disease in treatment market.

About Us
Persistence Market Research (PMR) is a U.S.-based full-service market in-telligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexi-ble without compromising on its deep-seated research values.

Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com

This release was published on openPR.